X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Clinical trial data transparency is the right thing to do

By Guest Contributor  |    September 30, 2015
By Dr. Murray Stewart, Chief Medical Officer, GSK At times, there can be a huge gulf between principle and practice. For example, eating healthy foods and getting lots of exercise are clearly...   Read More

Helping patients in times of need

By John Castellani  |    September 29, 2015
When Hurricane Katrina hit, the lack of communication between public health officials and the private sector, which controls most of the biopharmaceutical supply chain system slowed.  This gap...   Read More

Celebrating cardiovascular health on World Heart Day 2015

By Hannah Mooney  |    September 29, 2015
Today, we celebrate more heartbeats with World Heart Day. With a focus on cardiovascular disease and the promoting of healthier heart hygiene, World Heart Day is an opportunity to acknowledge...   Read More

Medicare Monday: What is ASP?

By Kelsey Lang  |    September 28, 2015
We’ve written previously about Medicare Part B and what it covers, but today we are taking a closer look at how Medicare Part B pays for medicines. With some exceptions for certain classes, the...   Read More

Week in Review: The Latest from PhRMA

By Priscilla VanderVeer  |    September 25, 2015
Protecting Innovation: The current marketplace for prescription medicines helps keep spending in check and continued innovation for patients possible. A recent proposal by Presidential Candidate...   Read More

New report: Eliminating hepatitis C today could reduce future U.S. health care spending by $115 billion over the next decade

By Holly Campbell  |    September 24, 2015
Costs and Consequences is a blog series examining the health care burden of not treating diseases. Too often, the rhetoric focuses solely on the cost of medicines and disregards the adverse...   Read More

National Drug Take Back Day

By Priscilla VanderVeer  |    September 24, 2015
The biopharmaceutical industry believes that any community-driven drug disposal program should involve local law enforcement and be structured to prevent drug abuse and diversion. This Saturday,...   Read More

340B Spotlight: Health Care Costs Rising from Increase in 340B Hospital Acquisitions of Physician Practices

By Rebecca Davison  |    September 24, 2015
An increasingly popular and alarming trend among 340B hospitals is hurting the integrity of the program and driving up health care costs in the system. Many 340B hospitals are rapidly acquiring...   Read More

New poll finds majority of voters oppose government price-setting for prescription drugs

By Robert Zirkelbach  |    September 23, 2015
Majority of voters (51 percent compared to 36 percent) oppose allowing the federal government to set the price of prescription medicines, a poll released today found. The Morning Consult poll of...   Read More

Real world evidence: Not just “big data”

By Guest Contributor  |    September 22, 2015
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today's challenges and opportunities. The Catalyst welcomes guest...   Read More

Secretary Clinton’s proposal would turn back the clock on medical innovation

By John Castellani  |    September 22, 2015
The sweeping proposals outlined in Secretary Clinton’s plan to regulate prescription drug prices would restrict patients’ access to medicines, result in fewer new treatments for patients, cost...   Read More

Medicare Monday: Putting MedPAC’s 19% in context

By Allyson Funk  |    September 21, 2015
If you pay attention to Medicare, you’ve probably heard of MedPAC or the Medicare Payment Advisory Commission. MedPAC is an independent congressional agency that advises Congress on issues related...   Read More

Week in Review: The Latest from PhRMA

By Priscilla VanderVeer  |    September 18, 2015
Small Increase in Price Over Time:  A new analysis from SSR Health found that after rebates and discounts, brand-name prescription medicine prices rose just 0.7 percent in the second quarter from...   Read More

Australia’s opportunity to lead the TPP forward

By Jay Taylor  |    September 18, 2015
New Australian Prime Minister Malcolm Turnbull is certainly going to have a busy autumn. As he works to form a new government, Australia must also strive to complete negotiations in the...   Read More

340B Spotlight: A lack of charity care among 340B hospitals

By Allyson Funk  |    September 17, 2015
We’ve talked before about charity care and the 340B drug discount program. Research  found most 340B hospitals provide little to below average levels of charity care. Why is this important?...   Read More

ICYMI: New survey finds most patients unaware of clinical pathways

By Holly Campbell  |    September 16, 2015
In case you missed it, a new survey from CancerCare of more than 1,300 breast, colon, lung and prostate cancer patients diagnosed within the past five years found that the vast majority had not...   Read More

Thanking Research and Hope honorees for their efforts fighting cancer

By Guest Contributor  |    September 15, 2015
Each year, PhRMA and other biopharmaceutical industry leaders honor those who have made a significant contribution to the health care field. The Research and Hope Awards recognize the men and...   Read More

Health coverage resources in Spanish

By Andrew Powaleny  |    September 15, 2015
More than 50 million Hispanics call the United States home and in 2013, Hispanic Americans accounted for nearly one-third of the non-elderly uninsured population. As Hispanic Heritage Month...   Read More

ICYMI: New analysis shows U.S. brand-name medicines rose just 0.7 percent in second quarter

By Holly Campbell  |    September 14, 2015
In case you missed it, a new analysis from SSR Health found after rebates and discounts, brand-name prescription drug prices rose just 0.7 percent in the second quarter from the previous year. ...   Read More

Medicare Monday: Adherence in Medicare and Medicaid saves money

By Allyson Funk  |    September 14, 2015
If you’ve been following along with Medicare Monday, you’ve undoubtedly heard us talk about how adherence to prescription medicines helps save money in Medicare. Due to a growing body of evidence,...   Read More

Week in Review: The Latest from PhRMA

By Priscilla VanderVeer  |    September 11, 2015
Medicines in Development: According to the latest Medicines In Development report, America’s biopharmaceutical research companies are currently developing 836 medicines and vaccines to treat...   Read More

PhRMA Honors Research & Hope Award Recipients

By Ieva M. Augstums  |    September 11, 2015
Imagine a world without cancer. Earlier this week, a group of trailblazers in the oncology community gathered to reflect on efforts to help make this dream a reality. PhRMA was pleased to host the   Read More

5 Reasons why biopharmaceutical patents are different

By Mark Grayson  |    September 10, 2015
Intellectual property protection has deep, historical roots in the United States.  Article I, Section 8 of the U.S. Constitution expressly recognizes the role of patents to “promote the Progress...   Read More

New PhRMA Report: 836 medicines and vaccines in development to treat cancers

By Tina Stow  |    September 10, 2015
Almost all of us have fought – or know someone who is fighting – the ruthless disease author Siddhartha Mukherjee termed, “the emperor of all maladies.” Today, cancers remain the second-leading...   Read More

How 340B discounts work

By Rebecca Davison  |    September 9, 2015
Recognizing the importance of access to prescription medicines, Congress created the 340B program in 1992 to help vulnerable or uninsured patients served by safety net facilities get the medicines...   Read More

Study: Better use of prescription drugs by Medicaid beneficiaries can yield significant savings

By Samantha Dougherty  |    September 9, 2015
If Medicaid beneficiaries adhered to their prescription drug regimens, they could significantly reduce U.S. medical costs, by reducing expensive hospitalizations and emergency room visits. A new...   Read More

Value at the crossroads, part II

By Randy Burkholder  |    September 8, 2015
Value assessment in health care continues to generate considerable interest, as reflected in the wide range of comments sent to the American Society of Clinical Oncology (ASCO) on their Value...   Read More

Medicare Monday: Resources for understanding Medicare Part B and D

By Andrew Powaleny  |    September 7, 2015
Earlier this summer, PhRMA released its new chart pack on biopharmaceuticals in government programs. It serves as a great resource for key facts and figures about major government programs,...   Read More

ICYMI – New York Times Editorial Board: Hepatitis C medicines a high value for patients and health care system

By Tina Stow  |    September 4, 2015
In a September 2 editorial, The New York Times Editorial Board concludes that “competitive market forces and hard-nosed bargaining” make “tremendously effective” new hepatitis C medicines not just...   Read More

PDUFA 101

By Andrew Powaleny  |    September 3, 2015
With Prescription Drug User Fee Act (PDUFA) VI FDA-Industry negotiations about to commence, we’re taking a look at what PDUFA is, how it works, and explaining why it has been a tremendous success...   Read More

5 Things You Didn’t Know about Researching and Developing a New Medicine

By Emma Van Hook  |    September 2, 2015
Unless you work in biopharmaceutical research and development (R&D), chances are the process of developing new medicines seems like a black box. It is hard to imagine how researchers go from an...   Read More

340B Mega Guidance

By Allyson Funk  |    September 1, 2015
PhRMA appreciates the Health Resources and Services Administration’s (HRSA) efforts in releasing the 340B mega guidance and is pleased to have an opportunity to comment before the guidance is...   Read More

#pass4prostate: Tackling Prostate Cancer through Awareness, Research

By Guest Contributor  |    September 1, 2015
  Considering that 1 in 7 men will be diagnosed with prostate cancer at some point in their lives, I suspect nearly everyone reading this column has been touched by the disease – whether as a...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates